鞘内注射利妥昔单抗治疗进展型多发性硬化:一项开放标签1b期研究
这项开放标签1b期研究在23例进展型多发性硬化患者中,经右侧额角置入脑室导管并连接皮下Ommaya储液囊,给予3剂利妥昔单抗(25 mg,间隔1周)鞘内注射,随访1年。结果显示治疗耐受性良好,常见轻度至中度眩晕和恶心,但发生1例低毒力细菌性脑膜炎;7项临床评估中仅1项在治疗1年后有统计学显著改善,6种脑脊液生物标志物未见治疗效应。作者指出无对照组限制疗效结论,并提示存在注射相关感染风险。
要点
- 23例进展型多发性硬化患者接受3剂利妥昔单抗25 mg鞘内注射,间隔1周。
- 常见不良事件为轻度至中度眩晕和恶心,均为暂时性。
- 唯一严重不良事件为1例低毒力细菌性脑膜炎,治疗有效。
核心结论
- 鞘内注射利妥昔单抗耐受性良好,但可能涉及注射相关感染风险。
- 缺乏对照组,无法就治疗疗效得出结论。
- 本研究提供IV级证据表明鞘内利妥昔单抗治疗在进展型多发性硬化中耐受性良好且可行,但涉及严重感染风险。
研究设计与样本
- 开放标签1b期研究,纳入23例进展型多发性硬化患者。
- 经置入右侧额角的脑室导管连接皮下Ommaya储液囊,给予3剂利妥昔单抗25 mg,间隔1周。
- 在1、3、6、9、12个月进行随访。
- 临床试验注册号NCT01719159。
主要发现
- 轻度至中度眩晕和恶心常见但为暂时性不良事件,与鞘内利妥昔单抗输注相关,除此之外耐受性良好。
- 唯一严重不良事件为1例低毒力细菌性脑膜炎,治疗有效。
- 7项临床评估中仅1项在治疗1年后显示统计学显著改善。
- 随访期间6种脑脊液生物标志物未观察到治疗效应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 缺乏对照组,无法就治疗疗效得出结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To perform a phase 1b assessment of the safety and feasibility of intrathecally delivered rituximab as a treatment for progressive multiple sclerosis (PMS) and to evaluate the effect of treatment on disability and CSF biomarkers during a 1-year follow-up period. METHODS: Three doses of rituximab (25 mg with a 1-week interval) were administered in 23 patients with PMS via a ventricular catheter inserted into the right frontal horn and connected to a subcutaneous Ommaya reservoir. Follow-ups were performed at 1, 3, 6, 9, and 12 months. RESULTS: Mild to moderate vertigo and nausea were common but temporary adverse events associated with intrathecal rituximab infusion, which was otherwise well tolerated. The only severe adverse event was a case of low-virulent bacterial meningitis that was treated effectively. Of 7 clinical assessments, only 1 showed statistically significant improvement 1 year after treatment. No treatment effect was observed during the follow-up period among 6 CSF biomarkers. CONCLUSIONS: Intrathecal administration of rituximab was well tolerated. However, it may involve a risk for injection-related infections. The lack of a control group precludes conclusions being drawn regarding treatment efficacy. CLINICALTRIALSGOV IDENTIFIER: NCT01719159. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that intrathecal rituximab treatment is well tolerated and feasible in PMS but involves a risk of severe infections.
引用
- Bergman J, Burman J, Gilthorpe JD, et al. Intrathecal treatment trial of rituximab in progressive MS: An open-label phase 1b study. Neurology. 2018. PMID: 30305449. doi:10.1212/WNL.0000000000006500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。